First New Medicine for the Treatment of Hyperkalemia in More than 50 Years
VELTASSA (patiromer) for oral suspension is the first commercialized medicine resulting from Relypsa’s polymer technology platform.
VELTASSA® Indication & Limitations of Use
VELTASSA is a potassium binder approved for the treatment of hyperkalemia.
VELTASSA should not be used as an emergency treatment for life-threatening hyperkalemia because of its delayed onset of action.
Please see Important Safety Information.
Click here for full Prescribing Information.
Available in powder form, VELTASSA is mixed with water and taken daily. Its smooth, spherical beads bind to potassium in exchange for calcium, primarily in the colon. The potassium is then excreted from the body through the normal excretion process.
VELTASSA Patient Access Program
Relypsa is committed to providing people living with hyperkalemia a comprehensive network of patient support services.
Visit VELTASSA.com for more information.
Contraindications Veltassa is contraindicated in patients with a history of a hypersensitivity reaction to Veltassa or any of its components.
Worsening of Gastrointestinal Motility Avoid use of Veltassa in patients with severe constipation, bowel obstruction or impaction, including abnormal post-operative bowel motility disorders, because Veltassa may be ineffective and may worsen gastrointestinal conditions. Patients with a history of bowel obstruction or major gastrointestinal surgery, severe gastrointestinal disorders, or swallowing disorders were not included in clinical studies.
Hypomagnesemia Veltassa binds to magnesium in the colon, which can lead to hypomagnesemia. In clinical studies, hypomagnesemia was reported as an adverse reaction in 5.3% of patients treated with Veltassa. Approximately 9% of patients in clinical trials developed hypomagnesemia with a serum magnesium value < 1.4 mg/dL. Monitor serum magnesium. Consider magnesium supplementation in patients who develop low serum magnesium levels.
Adverse Reactions The most common adverse reactions (incidence ≥ 2%) are constipation, hypomagnesemia, diarrhea, nausea, abdominal discomfort and flatulence. Mild to moderate hypersensitivity reactions were reported in 0.3% of patients treated with Veltassa and included edema of the lips.
Please see full Prescribing Information by clicking here.